Candel Therapeutics will participate in three investor conferences in September 2026. Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, is scheduled for fireside discussions at Citi’s 2026 Biopharma Back to School Conference on September 9, the 2026 Cantor Global Healthcare Conference on September 10 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, all in New York. Candel is developing multimodal biological immunotherapies for cancer through adenovirus- and herpes simplex virus-based platforms. Its lead candidates include aglatimagene besadenovec, which has been studied in prostate cancer, non-small cell lung cancer and pancreatic ductal adenocarcinoma, and linoserpaturev, which is being evaluated in recurrent high-grade glioma.